Tianjin Pharmaceutical Da Ren Tang Overview

  • Status
  • Public

  • Employees
  • 3,835

Employees

  • Stock Symbol
  • 600329

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $4.88
  • (As of Tuesday Closing)

Tianjin Pharmaceutical Da Ren Tang General Information

Description

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Contact Information

Formerly Known As
Tianjin Zhongxin Pharmaceutical Group Corporation
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Zhong Xin Mansion
  • 17 Baidi Road Nankai District
  • Tianjin, 300193
  • China
+86
Primary Industry
Pharmaceuticals
Stock Exchange
SHG
Corporate Office
  • Zhong Xin Mansion
  • 17 Baidi Road Nankai District
  • Tianjin, 300193
  • China
+86

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tianjin Pharmaceutical Da Ren Tang Stock Performance

As of 15-Jul-2025, Tianjin Pharmaceutical Da Ren Tang’s stock price is $4.88. Its current market cap is $3.28B with 770M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.88 $4.62 $3.68 - $5.56 $3.28B 770M 5.16M $0.40

Tianjin Pharmaceutical Da Ren Tang Financials Summary

As of 31-Mar-2025, Tianjin Pharmaceutical Da Ren Tang has a trailing 12-month revenue of $927M.

In Thousands,
USD
TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 2,465,621 2,815,861 2,948,662 2,331,679
Revenue 926,620 1,018,295 1,162,184 1,224,917
EBITDA 358,869 378,532 170,562 156,045
Net Income 307,593 310,689 139,466 127,966
Total Assets 1,537,469 1,475,134 1,443,177 1,472,176
Total Debt 10,859 3,916 46,433 37,382
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tianjin Pharmaceutical Da Ren Tang Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tianjin Pharmaceutical Da Ren Tang Investments & Acquisitions (3)

Tianjin Pharmaceutical Da Ren Tang’s most recent deal was a Secondary Transaction - Private with Shike Pharma. The deal was made on 23-Nov-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Shike Pharma 23-Nov-2022 Secondary Transaction - Private Pharmaceuticals
Jing Wanhong 19-Sep-2022 Merger/Acquisition Medical Supplies
Shike Pharma 23-Sep-1984 Joint Venture Pharmaceuticals
To view Tianjin Pharmaceutical Da Ren Tang’s complete investments and acquisitions history, request access »

Tianjin Pharmaceutical Da Ren Tang ESG

Risk Overview

Risk Rating

Updated January, 18, 2025

35.88 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,697

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Pharmaceuticals

Subindustry

of 420

Rank

Percentile

To view Tianjin Pharmaceutical Da Ren Tang’s complete esg history, request access »

Tianjin Pharmaceutical Da Ren Tang Exits (2)

Tianjin Pharmaceutical Da Ren Tang’s most recent exit was on 23-Nov-2022 from Shike Pharma. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Shike Pharma 23-Nov-2022 Completed
Shike Pharma 23-Sep-1984 Joint Venture Completed
  • 2 buyers
To view Tianjin Pharmaceutical Da Ren Tang’s complete exits history, request access »

Tianjin Pharmaceutical Da Ren Tang Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Jing Wanhong Tianjin, China 1981

Tianjin Pharmaceutical Da Ren Tang FAQs

  • Where is Tianjin Pharmaceutical Da Ren Tang headquartered?

    Tianjin Pharmaceutical Da Ren Tang is headquartered in Tianjin, China.

  • What is the size of Tianjin Pharmaceutical Da Ren Tang?

    Tianjin Pharmaceutical Da Ren Tang has 3,835 total employees.

  • What industry is Tianjin Pharmaceutical Da Ren Tang in?

    Tianjin Pharmaceutical Da Ren Tang’s primary industry is Pharmaceuticals.

  • Is Tianjin Pharmaceutical Da Ren Tang a private or public company?

    Tianjin Pharmaceutical Da Ren Tang is a Public company.

  • What is Tianjin Pharmaceutical Da Ren Tang’s stock symbol?

    The ticker symbol for Tianjin Pharmaceutical Da Ren Tang is 600329.

  • What is the current stock price of Tianjin Pharmaceutical Da Ren Tang?

    As of 15-Jul-2025 the stock price of Tianjin Pharmaceutical Da Ren Tang is $4.88.

  • What is the current market cap of Tianjin Pharmaceutical Da Ren Tang?

    The current market capitalization of Tianjin Pharmaceutical Da Ren Tang is $3.28B.

  • What is Tianjin Pharmaceutical Da Ren Tang’s current revenue?

    The trailing twelve month revenue for Tianjin Pharmaceutical Da Ren Tang is $927M.

  • What is Tianjin Pharmaceutical Da Ren Tang’s annual earnings per share (EPS)?

    Tianjin Pharmaceutical Da Ren Tang’s EPS for 12 months was $0.40.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »